Fig. 4.

Survival analysis correlated with augmentation of immunological responses. Progression free survival (PFS) and overall survival (OS) of nine patients with increased IgG levels for at least one peptide within ten vaccinations compared to four patients without increased IgG levels are indicated in a and c, respectively. Increased peptide-specific IgG levels correlated with only OS with statistical significance (P = 0.0215). PFS and OS of ten patients with an augmented CTL response for at least one peptide within ten vaccinations compared to two patients without an augmented CTL response are indicated in b and d, respectively. This vaccine induced CTL responses with high frequency but did not show a survival benefit